Coronavirus Treatment Acceleration Program for NAS150

New Amsterdam Sciences, a privately held company, announces the filing of the Company’s newly provided materials and data with the FDA’s coronavirus treatment acceleration program as a pre-Investigation New Drug Phase 2 submission.. Read More

New EVP Brings Wealth of Government Agency Experience

New Amsterdam Sciences, a privately held bio- science company, announces Christopher van de Wetering, Ph.D. as Executive Vice President. Dr. van de Wetering is charged with general operations management, preclinical and clinical drug development including manufacturing and formulation as well as bringing the Company’s anti-inflammatory therapeutic for treatment of COVID-19… Read More

Arizona News - Dr. Christopher Van de Wetering | A False sense Of Security That The Vaccine Is 100% Protective

In The News


Covid Hot Spots